SOPs for Analytical Method Development V 2.0

This SOP outlines a structured approach for the optimization of isocratic HPLC methods used for analyzing pharmaceutical substances. It includes the selection of suitable columns, mobile phase composition, buffer strength, detection wavelength, and flow rate to achieve reproducible retention times and efficient separation with minimal baseline noise.
Click to read the full article.

This SOP outlines the procedure for systematic development and optimization of UPLC (Ultra Performance Liquid Chromatography) methods for the analysis of pharmaceutical raw materials, intermediates, and finished products. The aim is to improve resolution, reduce run time, and enhance overall method sensitivity and efficiency.
Click to read the full article.

This SOP provides a standard approach for selecting a suitable HPLC column and mobile phase during analytical method development to achieve optimal separation, reproducibility, and system suitability for pharmaceutical substances and products.
Click to read the full article.

This SOP describes the procedure for evaluating peak purity using a Photodiode Array (PDA) detector during HPLC method development. Peak purity assessment is essential to confirm that an analyte peak is not co-eluted with impurities or degradants and that it represents a single chemical entity.
Click to read the full article.

This SOP describes the procedure for conducting specificity studies using HPLC during analytical method development. Specificity ensures that the analytical method can measure the target analyte accurately in the presence of other potential components such as impurities, degradation products, matrix excipients, and placebo formulations.
Click to read the full article.

This SOP defines the systematic process for developing robust and validated HPLC-based assay methods to determine the quantity of active pharmaceutical ingredients (APIs) in finished dosage forms. The aim is to ensure precision, accuracy, and specificity as per ICH Q2(R1) guidelines.
Click to read the full article.

This SOP describes the procedure for developing High Performance Liquid Chromatography (HPLC) methods for the quantitative analysis of drug release in dissolution studies. It is intended to ensure reproducible and accurate profiling of drug dissolution over multiple time points, meeting regulatory standards.
Click to read the full article.

This SOP defines the procedure for developing an HPLC-based analytical method for content uniformity testing of solid oral dosage forms. The method ensures that each dosage unit contains the intended amount of active ingredient within acceptable pharmacopeial limits.
Click to read the full article.

This SOP defines the procedure for developing an HPLC method to detect and quantify related substances, including known and unknown impurities, degradants, and process-related impurities in active pharmaceutical ingredients (APIs) and finished drug products.
Click to read the full article.

This SOP outlines the procedure for the development and validation of HPLC methods for profiling degradation products of pharmaceutical active ingredients and formulations. The objective is to identify potential degradants through stress testing and ensure method suitability for stability-indicating purposes.
Click to read the full article.